Sinclair IS Pharma Plc Now Covered by Analysts at Numis Securities Ltd (SPH)
Equities research analysts at Numis Securities Ltd initiated coverage on shares of Sinclair IS Pharma Plc (LON: SPH) in a research note issued to investors on Wednesday. The firm set a “buy” rating and a $0.55 (36 GBX) price target on the stock.
Separately, analysts at Investec raised their price target on shares of Sinclair IS Pharma Plc from $0.57 to $0.59 in a research note to investors on Wednesday, February 20th. They now have a “buy” rating on the stock.
Sinclair IS Pharma Plc traded up 0.95% on Wednesday, hitting GBX 26.50. Sinclair IS Pharma Plc has a 52-week low of GBX 20.928 and a 52-week high of GBX 29.411. The stock’s 50-day moving average is currently GBX 27.46.
Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.